Novel Anti-Inflammatory Flops for HFpEF, HFmrEF

(MedPage Today) -- CHICAGO -- The novel myeloperoxidase (MPO) inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection fraction (HFmrEF, HFpEF), the phase II ENDEAVOR...